



Life Settlement Assets PLC – Ordinary Share A

Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

Commentary

The 24th Annual Spring Life Settlement Conference was held in May by LISA (Life Insurance Settlement Association) in Washington, D.C. The experts presented recent regulatory changes and technology renovations which could bring the industry to the next level, with a focus on streamlining the process of transactions such as short-form underwriting. Such advances could have the potential to not only transact a much larger number of policies before they lapse, but also to make a life settlement or viatical settlement transaction much more accessible for millions of American seniors.

The Share Class is reporting a performance of 0.14% for the month of May. Five HIV maturities have been registered, contributing a total Death Benefit of \$569k. Three maturities were registered in the elderly segment, for a total coverage of \$445k. Currently, our estimation of A/E ratio for the HIV segment until May is about 130%. However, the elderly segment continues to underperform due to the lack of any large size policies maturing. In addition, a small portfolio of fractionals, to which the trust was overwhelmingly already exposed to, was added.

Investment Terms	Estimated NAV (USD)	NAV/Share
1.5% Management Fee	92,739,487.94	2.0406

Number Of Policies	Death Benefits (USD)	Matured Policies YTD*		Maturities YTD (USD)*
4 667	463 935 494	60		7 163 008
Trust Investment Manager	Acheron Capital Ltd.	Company Secretary	Maitland Administration Services Limited	
Administrator	Compagnie Européenne de Révisic	on ISIN Ticker	GB00BF1Q4B05 LSAA	
Auditor	Grant Thornton UK LLP	Info	life@acheroncapital.com +44 207 258 5990	





May 2018

100%

90%

80%

70%

60%

50%


40%

30%

20%


10%


0%



Distribution By Gender

Distribution by Insurance Company






(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.
(2)Distribution by issue dates reflects the time since the life insurance policy was issued.
Source of Data: Acheron Capital Ltd unless otherwise stated.

May 2018








Maturities May 2018

Number of policies matured in May 2018	8
Corresponding number of insured	6
Total death benefit in May 2018(US\$)	1 014 413
Valuation of Matured policies in Book (US\$)	199 835



Premiums Situation (US\$)⁽¹⁾

Servicers Premiums Projection as of Beginning 2018	\$ 13.4M
Mortality Adjusted Premiums Projection Beginning 2018	\$ 12.1M
Estimated COI Net of Mortality Beginning 2018	\$ 11.2M

Top 10 Coverage

Cash Situation (US\$)⁽¹⁾

		Total Face	Age		Cash at hand and similar	\$ 19.1M
Insured	Face (millions)	(millions)	•	Expiration Age*	Gross Cash in Policies ⁽²⁾	\$ 41.7M
1	7.6/2.1/0.9	10.6	98	101/101/101	(estimated as of end 2017)	Ş 41.7 WI
2	9.6	9.6	97	100		
3	3.0/2.6/1.7	7.3	98	115/120/120	Loan on Cash in Policies	\$ 22.2M
4	1.9/1.4	3.3	94	100/100	(estimated as of end 2017)	
5	1.2/0.8/0.6	2.6	75	121/100/100	Net Cash in Policies ⁽²⁾	\$ 19.5M
6	1.2/0.8/0.3/0.1/0.1/0.1	2.6	90	100/100/100/95/100/115	(estimated as of end 2017)	
7	1.3/1.0	2.3	94	100/115	Maturities to be received	\$ 3.4M
8	2.2	2.2	93	100		
9	2.2	2.2	92	100		
10	1.9	1.9	77	100		

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Cash for fractional policies and ABC policies not included. Surrender charge included. *In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.